MA27835A1 - Methodes pour le traitement de l'atherosclerose, des dyslipemies et conditions apparentees et compositions pharmaceutiques - Google Patents

Methodes pour le traitement de l'atherosclerose, des dyslipemies et conditions apparentees et compositions pharmaceutiques

Info

Publication number
MA27835A1
MA27835A1 MA28589A MA28589A MA27835A1 MA 27835 A1 MA27835 A1 MA 27835A1 MA 28589 A MA28589 A MA 28589A MA 28589 A MA28589 A MA 28589A MA 27835 A1 MA27835 A1 MA 27835A1
Authority
MA
Morocco
Prior art keywords
atherosclerosis
treatment
dyslipemia
methods
pharmaceutical compositions
Prior art date
Application number
MA28589A
Other languages
English (en)
Inventor
Kang Cheng
M Gerard Waters
Kathleen M Metters
Gary O'neill
Original Assignee
Merck & Co Inc
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27835(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc, Merck Frosst Canada Ltd filed Critical Merck & Co Inc
Publication of MA27835A1 publication Critical patent/MA27835A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

EXTRAIT Une méthode pour le traitement de l'athérosclérose est révélée oé l'acide nicotinique ou autre agoniste du récepteur de l'acide nicotinique est administré à un patient en combinaison avec un antagoniste du récepteur de DP. L'antagoniste du récepteur de DP est administré pour réduire, prévenir ou éliminer la bouffée congestive qui pourrait autrement se produire.
MA28589A 2003-05-15 2005-11-09 Methodes pour le traitement de l'atherosclerose, des dyslipemies et conditions apparentees et compositions pharmaceutiques MA27835A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47066503P 2003-05-15 2003-05-15

Publications (1)

Publication Number Publication Date
MA27835A1 true MA27835A1 (fr) 2006-04-03

Family

ID=33476734

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28589A MA27835A1 (fr) 2003-05-15 2005-11-09 Methodes pour le traitement de l'atherosclerose, des dyslipemies et conditions apparentees et compositions pharmaceutiques

Country Status (44)

Country Link
US (4) US20040229844A1 (fr)
EP (3) EP2286816A1 (fr)
JP (2) JP4637833B2 (fr)
KR (2) KR100960749B1 (fr)
CN (3) CN101559227B (fr)
AR (1) AR041089A1 (fr)
AU (2) AU2004240597B2 (fr)
BR (1) BRPI0410273A (fr)
CA (1) CA2525772C (fr)
CL (1) CL2004001056A1 (fr)
CO (1) CO5630034A2 (fr)
CR (2) CR8047A (fr)
CY (2) CY1109476T1 (fr)
DE (1) DE602004022036D1 (fr)
DK (2) DK2116244T3 (fr)
DO (1) DOP2004000907A (fr)
EA (2) EA009744B1 (fr)
EC (1) ECSP056156A (fr)
ES (2) ES2328148T3 (fr)
GE (2) GEP20105025B (fr)
GT (1) GT200400098A (fr)
HN (1) HN2004000171A (fr)
HR (2) HRP20090424T1 (fr)
IL (1) IL171962A (fr)
IS (1) IS2708B (fr)
JO (1) JO2564B1 (fr)
MA (1) MA27835A1 (fr)
ME (1) MEP60108A (fr)
MX (1) MXPA05012272A (fr)
MY (1) MY140639A (fr)
NO (1) NO20055957L (fr)
NZ (2) NZ572515A (fr)
PA (1) PA8603201A1 (fr)
PE (1) PE20050552A1 (fr)
PL (2) PL1624871T3 (fr)
PT (2) PT1624871E (fr)
RS (3) RS20120499A1 (fr)
SG (1) SG153667A1 (fr)
SI (2) SI2116244T1 (fr)
TN (1) TNSN05290A1 (fr)
TW (2) TWI341199B (fr)
UA (1) UA89615C2 (fr)
WO (1) WO2004103370A1 (fr)
ZA (1) ZA200508288B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60215000T2 (de) * 2001-05-23 2007-08-09 Merck Frosst Canada & Co, Kirkland Dihydropyrroloil[1,2-a]indol- und Tetrahydropyridol[1,2-a]indol-Derivate als Prostaglandin-D2-Rezeptor-Antagonisten
US7094572B2 (en) * 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
SI1799196T1 (sl) 2004-10-08 2016-10-28 Forward Pharma A/S Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006078776A2 (fr) * 2005-01-19 2006-07-27 The Trustees Of The University Of Pennsylvania Inhibiteurs et procedes de traitement de maladies cardio-vasculaires, et procede pour l'identification d'inhibiteurs
CA2598273A1 (fr) * 2005-02-17 2006-08-24 Merck & Co., Inc. Methode de traitement de l'atherosclerose, de dyslipidemies et de troubles lies
AU2006214286A1 (en) * 2005-02-18 2006-08-24 Arena Pharmaceuticals, Inc. Methods and compositions for the treatment of lipid-associated disorders
US7750015B2 (en) * 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0610133A2 (pt) * 2005-05-17 2010-06-01 Schering Corp heterociclos como agonistas de receptor de ácido nicotìnico para o tratamento de dislipidemia
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
JP2009507791A (ja) * 2005-08-29 2009-02-26 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、このような化合物を含有する組成物、および治療方法
AU2006284751A1 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
EP1940382A2 (fr) * 2005-10-07 2008-07-09 Aditech Pharma AB Polytherapie a base d' esters d' acide fumarique pour le traitement de maladies autoimmunes et/ou inflammatoires
CA2634235A1 (fr) * 2005-12-21 2007-07-05 Schering Corporation Combinaison d'un antagoniste/agoniste inverse de h3 et d'un moderateur de l'appetit
CA2634940A1 (fr) * 2005-12-21 2007-07-05 Schering Corporation Traitement de la steatose hepatique non alcoolique au moyen d'agents hypocholesterolemiants et/ou dun agoniste inverse/antagoniste du recepteur h3
AU2007208478A1 (en) * 2006-01-20 2007-08-02 Schering Corpooration Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
MX2009002918A (es) * 2006-09-15 2009-03-31 Schering Corp Derivados azetidinona y sus metodos de uso.
MX2009002921A (es) * 2006-09-15 2009-04-01 Schering Corp Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
WO2008033431A1 (fr) 2006-09-15 2008-03-20 Schering Corporation Dérivés d'azétidinone spirocyclique traitant les troubles du métabolisme des lipides, la douleur, le diabète et d'autres troubles
WO2008039882A1 (fr) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc Combinaison de niacine et d'un antagoniste du récepteur de prostaglandine d2
WO2008097535A2 (fr) * 2007-02-08 2008-08-14 Merck & Co., Inc. Procédé de traitement de l'athérosclérose, des dyslipidémies et d'états pathologiques apparentés
US20090076117A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched laropiprant
CN101559058B (zh) * 2008-04-16 2011-07-20 北京本草天源药物研究院 一种治疗血脂异常的药物组合物
RU2010151944A (ru) * 2008-05-20 2012-06-27 Серенис Терапьютикс С.А. (Fr) Ниацин и нспвс для комбинированной терапии
WO2010030360A1 (fr) 2008-09-11 2010-03-18 Arena Pharmaceuticals, Inc. Dérivés 3h-imidazo[4,5-b]pyridin-5-ol utiles dans le traitement de troubles du récepteur gpr81
WO2010036600A1 (fr) * 2008-09-24 2010-04-01 Merck Sharp & Dohme Corp. Compositions pharmaceutiques d’atorvastatine
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
EP2564839B1 (fr) 2009-01-09 2016-05-11 Forward Pharma A/S Formule pharmaceutique comportant un ou plusieurs esters d'acide fumarique dans une matrice érosive
MX2012010038A (es) 2010-03-16 2012-10-01 Aventis Pharma Inc Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2.
CA2793223A1 (fr) 2010-03-16 2011-09-22 Aventis Pharmaceuticals Inc. Pyrimidines substituees en tant qu'antagonistes du recepteur d2 de prostaglandines
JP6770522B2 (ja) 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
BE787444A (fr) * 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) * 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
WO1979000169A1 (fr) 1977-09-30 1979-04-05 Rca Corp Systeme programmateur de television
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US5021447A (en) * 1986-01-23 1991-06-04 Merck Frosst Canada, Inc. Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US4940719A (en) * 1986-03-27 1990-07-10 Merck Frosst Canada, Inc. Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) * 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5190972A (en) * 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AU5787996A (en) * 1995-04-19 1996-11-07 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
PT877750E (pt) 1995-10-31 2002-09-30 Schering Corp 2-azetidinonas substituidas por acucar uteis como agentes hipocolesterolemiantes
AU7472896A (en) 1995-11-02 1997-05-22 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
DK0814782T3 (da) 1995-12-22 2002-12-16 Nissan Chemical Ind Ltd Farmaceutisk præparat stabiliseret med et basisk middel
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5886171A (en) 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US20010006644A1 (en) * 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
EP1017390B1 (fr) * 1997-07-31 2007-04-18 Kos Life Sciences, Inc. COMPRIME ENROBE COMPRENANT DE L'ACIDE NICOTINIQUE OU UN COMPOSE METABOLISE EN ACIDE NICOTINIQUE A LIBERATION RETARDEE, ET D'INHIBITEUR DE REDUCTASE HMG-CoA A LIBERATION IMMEDIATE
CA2307068C (fr) * 1997-10-27 2007-04-10 Dr. Reddy's Laboratories Limited Composes bicycliques, procede de preparation et compositions pharmaceutiques les contenant
US6133001A (en) 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
CA2353981C (fr) 1998-12-07 2005-04-26 Schering Corporation Procede relatif a la synthese d'azetidinones
DE69911058T2 (de) 1998-12-23 2004-06-03 G.D. Searle Llc, Chicago Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
JP3679715B2 (ja) 1999-04-05 2005-08-03 シェーリング コーポレイション １−（４−フルオロフェニル）−３（ｒ）−［３（ｓ）−ヒドロキシ−３−（４−フルオロフェニル）プロピル）］−４（ｓ）−（４−ヒドロキシフェニル）−２−アゼチジノンの調製のための立体選択的微生物還元
AU4343500A (en) 1999-04-16 2000-11-02 Schering Corporation Use of azetidinone compounds
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
KR20030010589A (ko) 2000-03-09 2003-02-05 오노 야꾸힝 고교 가부시키가이샤 인돌 유도체, 그 제조 방법 및 용도
US20010047027A1 (en) * 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
JP2002008186A (ja) * 2000-06-23 2002-01-11 Mitsubishi Heavy Ind Ltd 車種識別装置
US6410583B1 (en) * 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
JP3889563B2 (ja) * 2000-09-13 2007-03-07 三洋電機株式会社 映像信号処理回路
EP1377834A2 (fr) 2001-04-11 2004-01-07 Glaxo Group Limited Medicaments modulateurs de hm74 et/ou de l'activite de hm74a
DE60215000T2 (de) * 2001-05-23 2007-08-09 Merck Frosst Canada & Co, Kirkland Dihydropyrroloil[1,2-a]indol- und Tetrahydropyridol[1,2-a]indol-Derivate als Prostaglandin-D2-Rezeptor-Antagonisten
EP1424335A4 (fr) 2001-09-07 2005-11-16 Ono Pharmaceutical Co Derives d'indole
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
CN100378083C (zh) * 2002-03-19 2008-04-02 小野药品工业株式会社 羧酸化合物和含有所述化合物作为活性成分的药物制剂
CN100402026C (zh) * 2002-06-03 2008-07-16 诺瓦提斯公司 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
JP4129960B2 (ja) * 2005-07-01 2008-08-06 タキゲン製造株式会社 ステー

Also Published As

Publication number Publication date
SI1624871T1 (sl) 2009-12-31
CR8047A (es) 2006-07-14
HN2004000171A (es) 2011-07-11
PT2116244E (pt) 2012-11-02
RS20120499A1 (sr) 2013-08-30
UA89615C2 (ru) 2010-02-25
EP2286816A1 (fr) 2011-02-23
EA200501817A1 (ru) 2006-06-30
EA009744B1 (ru) 2008-04-28
NO20055957L (no) 2006-02-14
CO5630034A2 (es) 2006-04-28
IL171962A (en) 2012-06-28
RS20050777A (sr) 2008-04-04
US20100076002A1 (en) 2010-03-25
GT200400098A (es) 2005-03-03
RS52731B (sr) 2013-08-30
DK2116244T3 (da) 2012-11-26
TWI334354B (en) 2010-12-11
MXPA05012272A (es) 2006-05-19
TWI341199B (en) 2011-05-01
US20110118292A1 (en) 2011-05-19
TW200503757A (en) 2005-02-01
AU2004240597B2 (en) 2011-01-06
EP1624871A1 (fr) 2006-02-15
CR9808A (es) 2008-07-29
PL1624871T3 (pl) 2009-12-31
CY1109476T1 (el) 2014-08-13
AU2011200986A1 (en) 2011-03-31
JP2010077151A (ja) 2010-04-08
GEP20105025B (en) 2010-06-25
GEP20084569B (en) 2008-12-25
KR20060012617A (ko) 2006-02-08
PE20050552A1 (es) 2005-08-06
PL2116244T3 (pl) 2013-01-31
NZ543399A (en) 2009-02-28
TW200803844A (en) 2008-01-16
CA2525772A1 (fr) 2004-12-02
CN102526735A (zh) 2012-07-04
JP4637833B2 (ja) 2011-02-23
JO2564B1 (en) 2010-11-03
CN100441184C (zh) 2008-12-10
CY1113342T1 (el) 2016-06-22
AU2011200986B2 (en) 2012-11-08
CN1787819A (zh) 2006-06-14
CL2004001056A1 (es) 2005-03-28
SI2116244T1 (sl) 2012-12-31
WO2004103370A1 (fr) 2004-12-02
CA2525772C (fr) 2011-03-15
US20040229844A1 (en) 2004-11-18
MEP60108A (en) 2011-05-10
PT1624871E (pt) 2009-09-07
IS2708B (is) 2011-01-15
TNSN05290A1 (en) 2007-07-10
JP2006526030A (ja) 2006-11-16
HRP20090424T1 (en) 2009-09-30
CN101559227A (zh) 2009-10-21
DK1624871T3 (da) 2009-11-16
IL171962A0 (en) 2006-04-10
AR041089A1 (es) 2005-05-04
DOP2004000907A (es) 2004-11-30
MY140639A (en) 2010-01-15
EP2116244B1 (fr) 2012-08-08
ES2392743T3 (es) 2012-12-13
KR100960749B1 (ko) 2010-06-01
SG153667A1 (en) 2009-07-29
EP1624871B1 (fr) 2009-07-15
ECSP056156A (es) 2006-04-19
KR100806008B1 (ko) 2008-02-26
IS8071A (is) 2005-10-13
EP2116244A1 (fr) 2009-11-11
US20090233977A1 (en) 2009-09-17
EA011895B1 (ru) 2009-06-30
ZA200508288B (en) 2008-08-27
PA8603201A1 (es) 2005-02-04
NZ572515A (en) 2010-07-30
ES2328148T3 (es) 2009-11-10
HRP20120818T1 (hr) 2012-11-30
KR20080003470A (ko) 2008-01-07
AU2004240597A1 (en) 2004-12-02
RS20120498A1 (sr) 2013-08-30
DE602004022036D1 (de) 2009-08-27
CN101559227B (zh) 2012-03-21
EA200702674A1 (ru) 2008-04-28
HK1092722A1 (zh) 2007-02-16
BRPI0410273A (pt) 2006-05-16

Similar Documents

Publication Publication Date Title
JO2564B1 (en) A method for treating atherosclerosis, lipodystrophy and related conditions and pharmaceutical compositions
UA115979C2 (uk) Таблетований препарат (4'-трифторметилфеніл)аміду (z)-2-ціано-3-гідроксибут-2-еноєвої кислоти з поліпшеною стійкістю
IT1282353B1 (it) Composizione farmaceutica, in particolare liquida, per sommanistrazione orale di ondansetron e metodi per la sua produzione
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
MA28437B1 (fr) Composes et leurs procedes d'utilisation
EP1478371A4 (fr) Methodes et produits permettant d'ameliorer des reponses immunitaires a l'aide de compose d'imidazoquinoline
TNSN01053A1 (fr) Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique
DE60129134D1 (en) O/w emulsion
MA54411B1 (fr) Compositions contenant de l'ibrutinib
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA27298A1 (fr) Compositions et procedes de dosage de liposomes de certaines tailles pour traiter ou prevenir une maladie
WO2001085257A3 (fr) Compositions d'antagoniste opioide et formes de dosage
MA27729A1 (fr) Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre
CY1116093T1 (el) Χρηση νιντεντανιμπης για την αγωγη της πνευμονικης ινωσεως
MA31437B1 (fr) Polypeptides, domaines variables d'anticorps et antagonistes
MA30528B1 (fr) Antagoniste du recepteur il-8.
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
NO20060328L (no) Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
EE200200463A (et) IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks või ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon
Gehin et al. Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist
MA29723B1 (fr) Composes
MA33602B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide
MA30665B1 (fr) Traitement de maladies rhumatoïdes avec des glucocorticoïdes a liberation retardee.
Steioff et al. Long term Rho-kinase inhibition ameliorates endothelial dysfunction in LDL-Receptor deficient mice